FIELD: medicine.
SUBSTANCE: group of inventions concerns ophthalmology and can be used for depression of level of serumal amyloid A protein (SAA) in tissues with glaucomatous changes, for diagnostics of glaucoma and determination of agents, potentially applicable for glaucoma treatment. The ways of SAA levels decrease provide contacting of glaucomatous tissues with agents which interact with a gene modulating SAA expression or inhibit interaction of the SAA protein with its receptor. Methods of diagnostics include obtaining of a biological material from the patient, analysis of the material and conclusion about glaucoma presence at detection of high level of bioactivity, mutation of genes or products of SAA genes. The method of determination agents, potentially applicable for glaucoma treatment includes modes of formation of the reactionary admixture containing cells, including the recombinant SAA protein or expression vectors, and an investigated bond; a stage of definition of effect of a signal transmission in the presence of a tested bond and conclusion formation about possibility of use of an agent for glaucoma treatment if there are changes of a signal transmission in the presence of a tested bond.
EFFECT: increase of efficiency of diagnostics and glaucoma treatment.
13 cl, 5 dwg, 1 tbl, 5 ex
